Pharmaceutical - Anti-virals

Filter

Current filters:

Anti-virals

Popular Filters

101 to 125 of 306 results

Janssen-Cilag files European approval of combination medicine for HIV-1

16-10-2013

US health care giant Johnson & Johnson subsidiary Janssen-Cilag International NV has submitted a Marketing…

Anti-viralsBiotechnologycobicistatDarunavirEuropeGilead SciencesJanssen-CilagJohnson & JohnsonPharmaceuticalRegulation

UK NICE final draft guidance on treatment for chronic hepatitis C

UK NICE final draft guidance on treatment for chronic hepatitis C

11-10-2013

The UK drugs watchdog the National Institute of Health and Care Excellence this morning confirmed its…

Anti-viralsEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferon

Janssen gains rights to Ph II hepatitis C candidate from GSK

08-10-2013

Janssen Pharmaceuticals has acquired the investigational compound GSK2336805, an NS5a replication complex…

Anti-viralsGlaxoSmithKlineGSK2336805JanssenJohnson & JohnsonLicensingPharmaceutical

ViiV Healthcare presents positive Tivicay results from HIV study

13-09-2013

Positive data has been reported from the Phase IIIb/IV FLAMINGO study of Tivicay (dolutegravir) versus…

Anti-viralsNorth AmericaPharmaceuticalResearchTivicayViiV Healthcare

AHF sues GSK for failing to provide discounts on HIV/AIDS drugs

11-09-2013

The USA-based AIDS Healthcare Foundation (AHF) said yesterday (September 10) that it has filed a law…

Anti-viralsGlaxoSmithKlineLegalNorth AmericaPharmaceuticalPricing

Roche in up to $422.5 million deal with Inovio Pharma

11-09-2013

Swiss drug major Roche (ROG: SIX) has signed an exclusive, worldwide license agreement with US drug developer…

Anti-viralsINO-1800INO-5150Inovio PharmaceuticalsLicensingOncologyPharmaceuticalRoche

Boehringer Ingelheim links with Presidio on interferon-free hepatitis C treatment regimens

10-09-2013

The US subsidiary of German family-owned drug major Boehringer Ingelheim says it has completed patient…

Anti-viralsBoehringer IngelheimdeleobuvirfaldaprevirPharmaceuticalPPI-668Presidio PharmaceuticalsResearch

Medivir and Daewoong drop hep C drug candidate

08-09-2013

Swedish infectious disease drug developer Medivir (STO:MVIR-B) said on Friday (September 6) that it has…

Anti-viralsDaewoongMedivirMIV-210PharmaceuticalResearch

In wake of Tivicay approval, MSF asks, "when will people in developing countries have access?"

13-08-2013

As the US Food and Drug Administration approved the new HIV drug Tivicay (dolutegravir) late Monday (The…

Anti-viralsdolutegravirGlobalHealthcarePharmaceuticalPricingTivicayViiV Healthcare

FDA approves new ViiV Healthcare HIV drug

13-08-2013

The US Food and Drug Administration yesterday (August 12) approved Tivicay (dolutegravir), a new drug…

Anti-viralsdolutegravirGlaxoSmithKlineNorth AmericaPfizerPharmaceuticalRegulationShionogiTivicayViiV Healthcare

AHF claims victory over FDA in HIV prevention drug case

08-08-2013

The USA-based AIDS Healthcare Foundation (AHF) says it won a key legal victory in a push for drug safety…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaPharmaceuticalRegulationTruvada

US FDA approves shipment of quadrivalent flu vaccine to health care providers

06-08-2013

The US subsidiary of UK pharma giant GlaxoSmithKline (LSE: GSK) says it has received Food and Drug Administration…

Anti-viralsFluarixGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationVaccines

Roche strikes deal with Medicines Patent Pool on medicines access

05-08-2013

Swiss drug major Roche (ROG: SIX) has entered into an agreement with the Medicines Patent Pool, a Geneva,…

Anti-viralsMarkets & MarketingPharmaceuticalPricingRocheValcyte

Vertex slumps as FDA delays hepatitis C trial

26-07-2013

US drug maker Vertex Pharmaceuticals (Nasdaq: VRTX) saw its shares drop 11% to $78 a share, in after-hours…

Anti-viralsBiotechnologyNorth AmericaPharmaceuticalRegulationResearchVertexVX-135

New Zealand consults on Victrelis listing and some Pegasys amendments

19-07-2013

New Zealand's Pharmaceutical Management Agency, PHARMAC, is seeking feedback on a proposal to list boceprevir…

Anti-viralsAsia-PacificBiotechnologyMerck & CoPegasysPharmaceuticalRegulationRocheVictrelis

UK's NICE recommends hepatitis C treatment for children

18-07-2013

In draft guidance published this week, the UK's drugs watchdog the National Institute for Health and…

Anti-viralsBiotechnologyEuropeMerck & CoPegasysPharmaceuticalPricingRegulationRocheViraferonPeg

Annual approvals of new drugs for neglected diseases nearly doubled since early 2000s and 2009-12; Tufts

14-07-2013

The annual number of new drug approvals worldwide to treat neglected diseases has nearly doubled in recent…

Anti-viralsPharmaceuticalRegulationResearchTropical diseases

Immunocore in multi-million deal with GlaxoSmithKline on ImmTACs

09-07-2013

Oxford, UK-based biotech firm Immunocore, focused on developing novel biological drugs called ImmTACs…

Anti-viralsBiotechnologyGlaxoSmithKlineImmunocoreLicensingOncologyPharmaceuticalResearch

Boehringer Ingelheim's all-oral interferon-free combination achieved 95% viral cure rates in genotype-1b hepatitis C

14-06-2013

New data from German family-owned drug major Boehringer Ingelheim's interferon-free SOUND-C3, presented…

Anti-viralsBoehringer IngelheimdeleobuvirfaldaprevirPharmaceuticalResearch

Bionor Pharma leaps on positive trial results of HIV vaccine Vacc-4x with Revlimid

14-06-2013

Norway-based Bionor Pharma (OSE: BIONOR) saw its shares leap 16% to 3.67 kroner on June 13, after the…

Anti-viralsBionor PharmaCelgenePharmaceuticalResearchRevlimidVacc-4xVaccines

BioLineRx collaborates with Chinese firm on hep C drug BL-8030

11-06-2013

Israeli drug developer BioLineRx (TASE: BLRX) has signed an out-licensing agreement with Jiangsu Chia-tai…

Anti-viralsAsia-PacificBioLineRxBiotechnologyBL-8030Chia-tai Tianqing PharmaceuticalLicensingPharmaceutical

101 to 125 of 306 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top